Wegovy Results at 3 Months: Separating Myth from Reality

The myth: if you're not down two stone by three months, it isn't working

This is probably the most common misconception our prescribers encounter. People arrive having read about 15% weight loss and expect to see most of it in the first quarter. The 15% figure comes from the STEP 1 trial, published in the New England Journal of Medicine, and it describes average weight reduction at 68 weeks, roughly a year and a half of treatment at the full 2.4mg maintenance dose. Three months is nowhere near that endpoint.

The dose-escalation schedule is the key context people miss. Wegovy starts at 0.25mg, steps up to 0.5mg after four weeks, then 1.0mg, then 1.7mg, before reaching 2.4mg, each step roughly four weeks apart. That means many people are still on 1.0mg or 1.7mg at the twelve-week mark. The therapeutic effect accumulates; it is not a switch flicked on day one.

What does three months actually look like? Weight loss figures from clinical programme data and real-world reporting suggest something in the region of 4–7% body weight for many people at around 12 weeks, though individual results vary widely. Someone starting at 100kg might have lost 4–7kg. That is meaningful. It is also not the whole story. If you are curious how the picture changes with a little more time, our two-month results guide shows where most people are mid-escalation.

What is actually happening in your body during those first twelve weeks

Semaglutide works as a GLP-1 receptor agonist, it mimics a gut hormone that signals fullness to the brain, slows gastric emptying and reduces appetite. The effect is dose-dependent, which is precisely why the escalation schedule exists: lower doses allow your digestive system to adjust, reducing the severity of nausea and other gastrointestinal effects that are more common early on.

For many people, the first noticeable change is not a number on the scales but a shift in how they relate to food. Portion sizes feel more manageable. The pull towards snacking between meals lessens. Eating past fullness becomes genuinely uncomfortable rather than just theoretically inadvisable. These changes are clinically important signals that the medicine is having its intended effect, even when weight loss feels slower than expected.

The NHS medicines information for semaglutide explains how the medicine works and what to expect during the early weeks, it is worth reading alongside your Patient Information Leaflet. Anyone with questions about side effects during the escalation period should contact their prescriber; changes to your dosing schedule are a clinical decision, not something to adjust based on what you have read online. Our guide on how long Wegovy takes to work goes into the timeline in more detail.

Side effects in the first three months: common, and usually manageable

The most frequently reported effects are gastrointestinal: nausea is the most common, followed by constipation, diarrhoea, vomiting and indigestion. These are most pronounced after starting or after a dose increase, and they generally ease as your body adjusts, often within a week or two of each step up.

Eating smaller portions, avoiding very fatty meals and staying well hydrated all help. The morning routine matters too: some people find taking their weekly injection on a consistent day of the week helps them plan around any mild nausea. If symptoms are severe or persistent, that is a conversation for your prescriber, not something to manage alone.

One serious but uncommon risk worth knowing: the MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as a known side effect of GLP-1 medicines. Severe, persistent abdominal pain that radiates to the back, with or without vomiting, is a reason to seek urgent medical attention. You can report any suspected side effect through the MHRA Yellow Card scheme.

For a broader look at the full Wegovy treatment picture (including eligibility and what the medicine is licensed for in the UK) the Wegovy treatment overview covers that ground. And if cost is a factor in your thinking, our guide to Wegovy costs in the UK explains what private treatment typically involves and how to read a price honestly.

How to judge whether your three-month results are on track

The most useful marker at twelve weeks is not a target percentage. It is the direction of travel. Is your weight moving downward, even slowly? Has your appetite changed? Are you tolerating the escalation? These are the questions a prescriber asks when reviewing your progress, and it is precisely why clinical oversight matters throughout treatment, not just at the start.

NICE's review criteria note that continuing Wegovy past six months on the maintenance dose is worth reassessing if less than 5% weight loss has occurred. Three months, and often still on a pre-maintenance dose, is too early to draw that conclusion. Patience is clinically appropriate here, not a sign of failure.

If you are weighing up how Wegovy compares to semaglutide results more broadly, or how the three-month window fits into the longer arc, the semaglutide results at 3 months page looks at the same evidence from a slightly different angle. And for anyone at an earlier stage, the one-month results guide sets realistic expectations for the very beginning of the journey.

Wegovy is a prescription-only medicine; it is not suited to everyone. If you would like a prescriber at our GPhC-registered pharmacy to review your situation, you can check your eligibility and start a free consultation through our treatment page.